Kuros Biosciences Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, Kuros Biosciences Ltd. has 39.44M shares outstanding.
| Shares Outstanding | 39.44M |
As of June 30, 2026, Kuros Biosciences Ltd. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.87 |
| Quick Ratio | 0.22 |
| Debt / Equity | 11.28 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 178.00 |
These figures are as of the close on October 22, 2026.
| 50-Day Moving Average | 20.17 |
As of June 30, 2026, Kuros Biosciences Ltd. holds 8.52M in cash and equivalents against 8.81M in total debt, resulting in a net debt position of -8.52M. Total book value stands at 78.13M, with working capital of 33.90M providing operational flexibility.
| Cash & Cash Equivalents | 8.52M |
| Total Debt | 8.81M |
| Net Debt | -8.52M |
| Equity (Book Value) | 78.13M |
| Book Value Per Share | 1.98 |
| Working Capital | 33.90M |
Kuros Biosciences Ltd.'s most recent stock split took place on October 8, 2020.
| Last Split Date | 10/8/2020 |
Already premium?